The Early Efficacy of Topical Levocabastine in Patients with Allergic Conjunctivitis  by Fujishima, Hiroshi et al.
The Early Efficacy of Topical
Levocabastine in Patients with
Allergic Conjunctivitis
Hiroshi Fujishima1, Kazumi Fukagawa1, Yoji Takano1, Shigeki Okamoto2, Yayoi Nakagawa3,
Eiichi Uchio4, Norihiko Yokoi5, Atsuki Fukushima6 and Etsuko Takamura7
ABSTRACT
Background: We investigated the early efficacy of topical levocabastine, an H1 histamine-receptor antago-
nist, in improving the clinical symptoms of allergic conjunctivitis.
Methods: Thirty-six patients with allergic conjunctivitis were enrolled. One drop of levocabastine was instilled
in one eye and one drop of artificial tears in the contralateral eye. Clinical examinations were performed before,
and 15 and 30 minutes after instillation. Symptoms of itching and signs of injection were assessed at each time
point.
Results: Both levocabastine and artificial tears resulted in a statistically significant reduction in ocular itching.
However, levocabastine was significantly more effective.
Conclusions: Although artificial tears had a positive effect in reducing symptoms of allergic conjunctivitis, by
the washing out of allergens, levocabastine was more effective than artificial tears in controlling acute symp-
toms of allergic conjunctivitis, demonstrating that the selective H1 histamine-receptor antagonist action of levo-
cabastine is rapidly effective in a clinical setting.
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INTRODUCTION
Allergic conjunctivitis is a common disease and is es-
timated to affect approximately 25% of the world
population. 1 The primary symptom of allergic con-
junctivitis is ocular itching; other signs include con-
junctival hyperemia or redness , chemosis , eyelid
swelling, ocular discharge, and lacrimation.2 A wide
range of treatments is currently available to the clini-
cian. These include mast cell stabilizers , antihista-
mines and steroids . Steroids inhibit multiple
mediator-induced allergic responses and are effective
in controlling symptoms and signs of allergic con-
junctivitis; however, possible complications including
cataracts and intraocular pressure elevation limit
their use. In contrast , mast-cell stabilizers such as
cromolyn (cromoglycic acid) inhibit more specific ac-
tions such as mast-cell degranulation and mediator
release , however these drugs often require up to
about a week to obtain satisfactory relief of symp-
toms. Artificial tears are also often used to wash out
allergens from the conjunctival sac.
Oral antihistamines are effective in controlling
symptoms such as itching but often induce side ef-
fects such as dehydration and drowsiness. Therefore,
in patients with predominantly ocular symptoms, topi-
cal preparations are preferable. Levocabastine hydro-
chloride, a second-generation antihistamine, is a non-
sedating , highly potent , selective H1 histamine-
receptor antagonist . A 0.025% suspension of levo-
cabastine has been developed in Japan for the treat-
ment of allergic conjunctivitis. In this study, we evalu-
ated whether the early efficacy of levocabastine is su-
perior to the wash-out effect of artificial tears. In this
study, the early efficacy of 0.025% levocabastine oph-
thalmic suspension and that of artificial tears were
Allergology International. 2006;55:301-303
ORIGINAL ARTICLE
1Department of Ophthalmology, Keio University School of Medi-
cine, 7Department of Ophthalmology, Tokyo Women’s Medical
University, Tokyo, 2Kozuka Eye Clinic, Ehime, 3Nakagawa Eye
Clinic, Osaka, 4Department of Ophthalmology, Yokohama City
University Medical Center, Kanagawa, 5Department of Ophthal-
mology, Kyoto Prefectural University of Medicine, Kyoto and 6De-
partment of Ophthalmology, Kochi Medical School, Kochi, Japan.
Correspondence: Hiroshi Fujishima, M.D., Department of Ophthal-
mology, Keio University School of Medicine, 35―Shinanomachi ,
Shinjuku-ku, Tokyo 160−8582, Japan.
Email: fhiroshi@sc.itc.keio.ac.jp
Received 11 January 2006. Accepted for publication 9 March
2006.
2006 Japanese Society of Allergology
Allergology International Vol 55, No3, 2006 www.jsaweb.jp 301
Fig. 1 Ocular itching in the early eficacy study. Though 
both artificial eye drops and levocabastine reduced ocular 
itching, levocabastine was more efective than artificial 
tears. ■: artificial tears, ◇: levocabastine. Values indicate 
means ± SD, paired t-test；＊p＜ 0.05 (artificial tears vs. 
levocabastine), #p＜0.05 (vs. pretreatment levels).
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Fig. 2 Objective bulbar conjunctival injection in the early 
eficacy study. Levocabastine was more efective in reduc-
ing bulbar conjunctival injection than artificial tears. ■: arti-
ficial tears, ◇: levocabastine. Values indicate means ± SD, 
paired t-test；＊ p＜ 0.05 (ar tificial tears vs. levocabastine), 
#p＜0.05 (vs. pretreatment levels).
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METHODS
Thirty-six patients (10 men and 26 women; mean age,
41.0 ± 15.4 years; range, 20―73 years) with allergic
conjunctivitis participated in the study. Patients were
examined at the Kozuka Eye Center in Ehime, the
Fujishima Eye Clinic in Niigata, or the Nakagawa Eye
Clinic in Osaka. The studies were performed from
August 2001 to March 2002.
Medical histories were recorded from all patients,
and written informed consents were obtained. The
following patients were excluded: 1) patients who had
any ocular surface diseases other than allergic con-
junctivitis, 2) patients who had used systemic or topi-
cal medications ( e . g . steroids , nonsteroidal anti-
inflammatory drugs , anticholinergics , immunosup-
pressives, mast-cell stabilizers, antihistamines) dur-
ing the past week, 3) patients younger than 20 years,
4) women who were pregnant or potentially pregnant,
and 5) patients who wore contact lenses.
Diagnoses were based on clinical symptoms and
slit-lamp examination. Patients were asked to grade
their baseline symptoms of ocular itching, conjuncti-
val redness, and foreign body sensation on a scale of
0 to 3 (0 = none, 1 = mild, 2 = moderate, 3 = severe).
Patients who had pre-treatment symptom grades that
differed by more than 1 between their eyes were ex-
cluded from the analysis to reduce the bias caused by
differences in symptom severity . Objective bulbar
conjunctival injection was also graded on a scale of 0
to 3 (0 = none, 1 = mild, 2 = moderate, 3 = severe)
based on slit-lamp examination. All the data are pre-
sented as means ± SD.
All patients were treated with one drop of levo-
cabastine (LivostinⓇ Eye Drops 0.025%, Santen Phar-
maceutical, Osaka, Japan) in one eye, and one drop of
artificial tear (Soft SantearⓇ, Santen Pharmaceutical)
in the contralateral eye. In order to avoid evaluation
bias, neither the patients nor examiners were notified
of the laterality of the eye drops. Symptoms and signs
were re-evaluated at 15 and 30 minutes after instilla-
tion.
Statistical Analysis―Paired t-tests were used to as-
sess the differences in symptoms before and after
treatment , and between levocabastine and artificial
tears. P values of less than 0.05 (two-tailed) were con-
sidered to indicate statistically significant differences.
RESULTS
Although both levocabastine and artificial tears sig-
nificantly reduced ocular itching compared with pre-
treatment levels, at 15 and 30 minutes (p < 0.001),
levocabastine was significantly more effective than ar-
tificial tears (p = 0.001 at 15 minutes and p < 0.001 at
30 minutes) (Fig. 1). Levocabastine reduced conjunc-
tival redness at both 15 and 30 minutes (p < 0.001)
compared with pretreatment levels , while artificial
tears reduced conjunctival redness only at 30 minutes
(p = 0.023). Levocabastine was also significantly more
effective in reducing conjunctival redness than artifi-
cial tears (p < 0.001 at 15 and 30 minutes) . Levo-
cabastine also significantly reduced foreign body sen-
sation in the eye compared with pre-treatment levels
at 15 (p = 0.001) and 30 minutes (p < 0.001). Treat-
ment with artificial tears did not significantly reduce
foreign body sensation . Levocabastine was clearly
more effective than artificial tears in reducing foreign
body sensation at both 15 (p = 0.005) and 30 minutes
(p = 0.001). Although both levocabastine (p < 0.001)
and artificial tears (p = 0.017) significantly reduced
bulbar conjunctival injection at 30 minutes , levo-
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cabastine was more effective than artificial tears (p <
0.001)(Fig. 2). No adverse events were observed dur-
ing this study.
DISCUSSION
In this study, artificial tears had a positive effect in re-
ducing symptoms of allergic conjunctivitis . Allergic
conjunctivitis is often complicated by dry eye and this
relationship has been studied in many studies.3,4 Al-
though artificial tears do not specifically treat allergy,
they augment the tear film, effectively “washing” the
ocular surface. This mechanism is useful for remov-
ing or reducing the concentration of allergens or pro-
teins that induce inflammation from the ocular sur-
face . Instillation of just one drop was sufficient to
bring about this positive effect in our study. This sug-
gests that more frequent instillation or washing with
greater volume of artificial tears might be even more
effective in improving the signs and symptoms of al-
lergic conjunctivitis.
In this study, we also compared the early efficacy
of artificial tears and levocabastine in the same pa-
tient by instilling one drug in one eye and the other
drug in the other eye. By this method, we excluded
bias arising from subjectivity of the patients’ evalu-
ation of symptoms and responses to the drugs.5 In
our study, topical levocabastine was more effective
than artificial tears in reducing ocular itching, con-
junctival redness, and foreign body sensation , and
also in reducing bulbar conjunctival injection as-
sessed by slit-lamp examination. These results dem-
onstrated that the selective H1 histamine-receptor an-
tagonist action of levocabastine is rapidly effective in
a clinical setting. The reduction of itching and vessel
permeability caused by histamine release by levo-
cabastine led to the decreased level of symptoms and
signs observed in this study.
In conclusion, our study demonstrated that both ar-
tificial tears and levocabastine were effective in reduc-
ing acute symptoms of allergic conjunctivitis . Levo-
cabastine however was significantly more effective
than artificial tears demonstrating that the selective
H1 histamine-receptor antagonist action of levo-
cabastine is rapidly effective in a clinical setting.
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